Lessons From Fingolimod for PPMS
The Secrets of Shapeshifting Cells
Old Drug Performs New Trick
Papers of the Week
Welcome to the Multiple Sclerosis Discovery Forum
To preserve brain health in multiple sclerosis, research suggests the optimal treatment regime starts early and closely monitors patients by MRI if possible to switch therapies before a disabling relapse.
What happens to the course of multiple sclerosis when people stop taking their drugs? It depends on the individual and on the drug. A new study may help answer the question better.
MS researchers have been looking to composite endpoints as more sensitive and meaningful measures of MS progression and disability for testing new drugs.
Depression may be the leading cause of disability and death among people with MS. Importantly, it's one of the few MS symptoms that can—and should— be completely reversed through treatment, says Adam Kaplin MD PhD.
Approximately 1 in 50 people with MS in British Columbia, Canada, developed drug-induced liver injury with about three months of exposure to interferon-beta IFN-β. The study of adverse drug reactions will help minimize or prevent the toxicity of MS drugs, a major clinical objective.
Wouldn't it be great to be able to predict who will develop MS? A new diagnostic test based on mutated antibody genes in B cells can identify patients with clinically isolated syndrome who are at high risk of converting to relapsing MS.
Multiple sclerosis (MS) is the most commonly acquired neurological disorder affecting young adults of reproductive age, but a German neurologist runs the only MS pregnancy registry in the world. A multidisciplinary group of clinicians are calling for a North American pregnancy registry to properly assess reproduction and child health, including the impact of disease modifying therapies and the MS disease itself on pregnancy outcome.
The few months after giving birth puts women with MS at higher risk of having a relapse. Resuming disease modifying therapies does not seem to help in the first six months postpartum, but breastfeeding exclusively may help, for surprising reasons. The biology is more complicated than first believed.
In what may be the first demonstration of myelin repair in people with multiple sclerosis, an old antihistamine shows modest improvement in the function of chronically demyelinated optic nerves.
Tools that will help investigators conceive and perform experimental work:
The Data Visualization section presents MS-related data in new ways, making it easy for viewers to discover unexpected relationships
Our latest data visualization presents a network map of the connections among 1253 authors of 263 research papers that reported results of clinical trials in progressive forms of multiple sclerosis between January 1983 and September 2015.
- Drug-Development Pipeline consolidates key information about compounds under investigation for therapeutic use
- Tissue Repositories lists features of the world's tissue repositories and brain banks, including rules of engagement and contact information
- Clinical Trials lists sources of information about MS clinical trials
Drug Database Updates:
The drug database, updated weekly from 5/14/2012 to 4/20/2016, contains detailed information about 44 approved and experimental drugs to treat multiple sclerosis, including clinical trials, regulatory actions, mechanisms of action, and side effects. Updates have been suspended due to lack of funding
Meetings and Events catalogs future and past meetings of interest to the MS-research community
- Funding Opportunities provides information about where to obtain grants
- Jobs offers descriptions of available positions
Member Directory displays profiles of MS-research community members
Bulletin Board allows MSDF members to post notices
Useful Links lists helpful resources elsewhere on the web
To whom it may concern,
From Dan Howitt regarding physical therapy.